Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Happel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 3.49
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 23.05
Financials
Revenue
$0.00-100.0%Net Income
$-13.95MEBITDA
$-13.95MFree Cash Flow
$-10.70MEPS (diluted)
$-0.26Shares Outstanding (diluted)
53.11M+139.5%Operating Expenses
$15.82MCash & Debt
$240.13MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-51.04M | $-1.58 |
| 2024 | $0.00 | $-45.57M | $-1.45 |
| 2023 | $2.00M | $-27.88M | $-1.53 |
| 2022 | $0.00 | $-30.50M | $-1.38 |
| 2021 | $0.00 | $-24.44M | $-1.10 |
| 2020 | $0.00 | $-11.37M | $-0.51 |
| 2019 | $0.00 | $-14.26M | $-0.64 |
Valuation
SGMThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·2d ago·Neutral
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
…ng of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose…
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
View source ↗ - Newsbenzinga.com·5d ago·Neutral
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
…lion Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares o…
View source ↗ - Newsglobenewswire.com·6d ago·Positive
… 2026 Sagimet to host a KOL event and webcast September 30, 2026 at 1 PM ET FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioSci…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
…ed to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.25 per share
Typical surprise +23.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.26 vs $-0.25miss
- Tue, May 12$-0.33 vs $-0.39beat
- Wed, Mar 11$-0.29 vs $-0.43beat
- Thu, Nov 13$-0.40 vs $-0.41beat
- Wed, Aug 13$-0.32 vs $-0.52beat
- Thu, May 8$-0.56 vs $-0.79beat
Estimates and results for SGMT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SGMT officers and directors.
- Bought
- $544k
- Sold
- $5.9m
2 trades
18 trades
- Kemble Georgesold
- Kemble Georgesold
- Happel Davidsold
- Rozek Elizabethsold
- Kemble Georgesold
- Happel Davidsold
- Chauche Thierrysold
- Martins Eduardo Brunosold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SGMT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.